C-PLM2712 North Inc
mitochondrial medicine, AI discovery, bifurcated stress response
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PLM2
C-PLM2C-PLM2mitochondrial medicine, AI discovery, bifurcated stress response
0-100 chain-logic scale · 15 dimensions · scored on public evidence
712 North states that it is building a drug-development and preclinical testing platform for neurodegeneration, focused on creating new therapies for rare and major neurodegenerative diseases. It presents its strategy as expanding its investigational product pipeline and pursuing contract research with strategic partners, and it grounds this mission in a proprietary mitochondrial target protease that it says is crucial for neuronal survival and supported by in vivo Alzheimer’s disease data.
Source712 North states that complex diseases such as Alzheimer’s dementia, heart failure, and cancer should be addressed through personalized mitochondrial medicines. The company says its approach combines mitochondrial biology with pharmaceutical drug development by targeting proteases of the mitochondrial inner membrane, and it believes these proteases must be profiled in each person to choose the right treatment rather than relying only on a medical diagnosis.
Source712 North Inc. presents itself as a Silicon Valley-style pharmaceutical company focused on creating new therapies and drugs for rare and major neurodegenerative diseases, especially aimed at making a difference for the blind. It states that its core belief is that success will come from building a drug-development and preclinical testing platform for neurodegeneration, supported by pipeline expansion, de-risking strategies, strategic partnerships, and collaboration across biotech, patient, and academic networks.
Source712 North states that it aims to pioneer personalized mitochondrial medicine for patients facing fatal aging-related diseases, specifically naming Alzheimer's dementia, heart failure, and cancer. The company presents this as its core mission and frames its operating beliefs around excellence, integrity, and efficiency, including the use of AI to advance R&D and reduce general and administrative costs.
Source712 North stated that it is developing personalized mitochondrial medicines for complex diseases including Alzheimer’s dementia, heart failure, and cancer. The company said its core belief is that mitochondrial inner membrane proteases are important and underused pharmaceutical targets, and that combining mitochondria biology with drug development can produce therapies for serious, often fatal disorders.
Source